Tisotumab vedotin治療復發性／轉移性子宮頸癌的檢視

The role of tisotumab vedotin in the management of recurrent/metastatic cervical cancer

Tisotumab vedotin（TV）乃一抗體藥物複合體（antibody-drug conjugate, ADC），美國在2021年通過TV可用來治療復發性/轉移性的子宮頸癌。ADC乃由人類單株抗體結合標靶，可以進入有此標記的細胞，然後釋放毒性分子，消滅含該標靶的腫瘤細胞。TV為單株抗體IgG1，進入含組織因子（tissue factor, TF）細胞內後，會釋放出甲基奧瑞化汀E（monomethyl auristatin E, MMAE），能毒殺含TF的腫瘤細胞。ADCs常見的副作用有出血、神經病變和眼疾（如結膜炎、潰瘍、角膜炎等）。現在正在進行第III期研究，使用TV合併不同的化學藥物來治療子宮頸癌。

Tisotumab vedotin (TV) is an antibody-drug conjugate (ADC) that was approval in the US in 2022 for the treatment of recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. Antibody drug conjugate is mediated by humanized monoclonal antibody binding to a target, either solely expressed or overexpressed on the surface of cancer cells and with a low expression in healthy tissues. Following target internalized, ideally through a cellular receptor, facilitating the direct delivery of the cytotoxic agent into the tumor cells. Tisotumab vedotin is comprised of an anti-tissue factor-(TF) monoclonal antibody IgG1 and monomethyl auristatin E (MMAE) that are combined with a protease-cleavable linker. Adverse effects included bleeding, neuropathy, and ocular events (conjunctivitis, ulceration, or keratitis), which are characteristic of ADCs. A randomized, phase III open-label study of this drug with different chemotherapeutic agents for cervical cancer patients is ongoing.